Submitted: 28 Jan 2018
Accepted: 10 May 2018
First published online: 01 Jun 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Renal Inj Prev. 2018;7(3):180-185.
doi: 10.15171/jrip.2018.43

Scopus id: 85050072991
  Abstract View: 312
  PDF Download: 265


Half dose of TauroLock; does it work? 

Sima Golmohamadi, Hamid Reza Omrani * , Nadia Asadi, Elaheh Sharifi, Mohammad Reza Zandkarimi

1 Nephrology Ward and Immunology Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
*Corresponding author: Hamid Reza Omrani; Email: Email:


Introduction: Bacteremia is one of the most important complications in central vein catheter used in hemodialysis. TauroLock is known as an effective catheter lock solution (antimicrobial plus anticoagulant solution) in preventing catheter-related bacteremia (CRB). However, its cost is high and not covered by the most insurance companies.

Objectives: The aim of this study is to investigate the effect of the medication as a half dose for its economic advantages.

Patients and Methods: In this clinical trial study, 152 patients were divided into case (n=62) and control groups (n=90). In the case group, for 1 year, TauroLock and heparin were injected into the catheter’s lumen (equal dose), but in the control group, only heparin was injected. For detecting bacteremia, blood cultures were obtained.

Results: According to the results, there was a significant difference in CRB between the two groups, at the base time, 3, 6 and 12 months after injection of TauroLock (P<0.05). There was a significant difference in CRB, at the base time, 3, 6 and 12 months, after injection of TauroLock for the case group (P<0.05), but there was no significant difference for the control group (P<0.05). A positive effect in decreasing CRB was seen in the patients, based on age, sex, BMI, duration of hemodialysis, level of serum albumin, diabetes mellitus history and serum ferritin.

Conclusion: The catheter lock solution TauroLock, even in half dose, after each hemodialysis session, could significantly decrease the rate of CRB in hemodialysis patients

Implication for health policy/practice/research/medical education:

Usage of TauroLock as an antimicrobial drug that prevents CRB has been recommended in most studies, but the high cost of the drug prevents its widespread use in hemodialysis patients. Therefore, in this study the effect of TauroLock as a half dose for its economic advantages was investigated.

Please cite this paper as: Golmohamadi S, Omrani HR, Asadi N, Sharifi E, Zandkarimi MR. Half dose of TauroLock; does it work? J Renal Inj Prev. 2018;7(3):180-185. doi: 10.15171/jrip.2018.43.

First name
Last name
Email address
Security code

Article Viewed: 312

Your browser does not support the canvas element.

PDF Downloaded: 265

Your browser does not support the canvas element.